Advances and challenges in modeling Charcot-Marie-Tooth type 2A using iPSC-derived models

Charcot-Marie-Tooth type 2A (CMT2A) is an inherited sensory-motor axonopathy caused by mutations in the Mitofusin2 (MFN2) gene, coding for MFN2 protein. No curative treatment has been developed to date. The advent of induced pluripotent stem cell (iPSC) has provided unprecedented opportunities to understand complex neurological disorders. In CMT2A research, patient-specific iPSCs can be differentiated in motor and sensory neurons, thereby establishing reliable in vitro disease models. Here, we review current available iPSC-based models of CMT2A, focusing on pathogenetic insights derived from these studies and discussing challenges and potential of iPSC-derived models in elucidating disease mechanisms, providing innovative platforms for testing, and developing novel effective therapeutic strategies.

Authors

Institutions

Publication Details

Journal
Stem Cell Reports
Published
2025-11-13
DOI
https://doi.org/10.1016/j.stemcr.2025.102711
Citations
1
Primary Topic
Hereditary Neurological Disorders
Type
article
Field-Weighted Citation Impact
0.91
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Advances and challenges in modeling Charcot-Marie-Tooth type 2A using iPSC-derived models

Giacomo P. Comi, M. D’Agostino, Valeria Parente, Elena Abati et al.
1 citations
Stem Cell Reports
Hereditary Neurological Disorders
0.91
article

Advances and challenges in modeling Charcot-Marie-Tooth type 2A using iPSC-derived models

Giacomo P. Comi, M. D’Agostino, Valeria Parente, Elena Abati, Stefania Paola Corti, Linda Ottoboni, Mafalda Rizzuti, Federica Rizzo, Elisa Pagliari
article en
1 citations

Abstract

Charcot-Marie-Tooth type 2A (CMT2A) is an inherited sensory-motor axonopathy caused by mutations in the Mitofusin2 (MFN2) gene, coding for MFN2 protein. No curative treatment has been developed to date. The advent of induced pluripotent stem cell (iPSC) has provided unprecedented opportunities to understand complex neurological disorders. In CMT2A research, patient-specific iPSCs can be differentiated in motor and sensory neurons, thereby establishing reliable in vitro disease models. Here, we review current available iPSC-based models of CMT2A, focusing on pathogenetic insights derived from these studies and discussing challenges and potential of iPSC-derived models in elucidating disease mechanisms, providing innovative platforms for testing, and developing novel effective therapeutic strategies.

Stem Cell ReportsVol. 20(12)
University of Milan (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Ospedale Maggiore (IT), Ferrari (Italy) (IT)
Openalex Percentile: Top 20%
Hereditary Neurological Disorders
0.91
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.